The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move that strengthens the legal protection of its core pharmaceutical products, Pfizer has secured a significant court victory securing Paxlovid's market position. The Federal Circuit Court of Appeals upheld a previous ruling cancelling a patent held by Enanta Pharmaceuticals, effectively ending infringement claims against the Covid-19 antiviral drug. The court's decision was based on discrepancies found in the chemical structure listed in an earlier patent application, leading to the invalidation of Enanta's US Patent No. 11,358,953.
This ruling comes as major pharmaceutical companies seek to protect profit margins from costly intellectual property disputes, sparing Pfizer from potential royalty liabilities or substantial damages. Looking at peer performance per market data, the sector faces mixed pressures; Merck (MRK) reported a 15% growth in sales for its rival drug Molnupiravir in the last quarter, while Paxlovid sales have softened globally as the pandemic phase transitions. Resolving this legal overhang is vital for Pfizer to maintain investor confidence in its long-term pipeline.
Sign in to access this content
Sign InInvestors are now monitoring PFE stock levels, which stood at $25.21 (at close June 18, 2026), with the price trading between a high of $25.66 and a low of $24.94. Regarding forward catalysts, the market is awaiting upcoming US Retail Sales data and the broader impact of recent Fed interest rate decisions on consumer healthcare spending. Pfizer's next quarterly earnings report will be the primary catalyst for assessing the company's strategy to offset declining pandemic-related revenues.